Dr. Ramalingam's present research involves developing immune checkpoint inhibitors and improving outcomes for patients with EGFR mutation.

Dr. Ramalingam holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research and International Association of Lung Cancer Study. He plays an active role in the ECOG-ACRIN Cancer Research Group as the Chair of the Thoracic Malignancies Committee and as the Deputy Chair of Therapeutics Programs. He serves on several international, national and institutional committees. He is a member of the Medical Oncology Board Exam Committee for American Board of Internal Medicine.